Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Venetoclax + Obinutuzumab
Treatment for Chronic lymphoid leukemia
Typical Dosage: Venetoclax ramp-up to 400mg daily, Obinutuzumab 1000mg IV on specific days
Effectiveness
92%
Safety Score
38%
Clinical Trials
45
Participants
6K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
38
DangerousModerateSafe
Treatment Details
Dosage Range
Venetoclax ramp-up to 400mg daily, Obinutuzumab 1000mg IV on specific days
Time to Effect
3-6 months
Treatment Duration
12-24 months
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$180,000
Monitoring:$7,000
Side Effect Mgmt:$8,000
Total Annual:$195,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$38,895/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$216,667
Cost per Remission
$325,000
Comparison vs Fludarabine + Cyclophosphamide + Rituximab
Cost Difference
+$130,000/year
More expensive
QALY Difference
+0.20 QALYs
Better outcomes
Dominance
No dominance
Venetoclax + Obinutuzumab Outcomes
for Chronic lymphoid leukemia
Efficacy Outcomes
Overall Effectiveness
+92%
Response Rate
+90%
Remission Rate
+60%
Common Side Effects
Neutropenia
+50%
Infections
+37%
Diarrhea
+30%
Nausea
+25%
Tumor Lysis Syndrome
+5%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
13 active trials recruiting for Venetoclax + Obinutuzumab in Chronic lymphoid leukemia
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
NCT04608318ACTIVE NOT RECRUITINGPHASE3
897 participants
INTERVENTIONAL
Graz, Austria +180 more
Started: Mar 1, 2021
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
NCT04895436RECRUITINGPHASE2
75 participants
INTERVENTIONAL
La Jolla, United States +57 more
Started: Mar 28, 2022
Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL
NCT04515238ACTIVE NOT RECRUITINGPHASE2
42 participants
INTERVENTIONAL
Augsburg, Germany +10 more
Started: Oct 1, 2020
The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)
NCT04447768ACTIVE NOT RECRUITINGPHASE2
100 participants
INTERVENTIONAL
Stanford, United States +7 more
Started: Dec 3, 2020
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
NCT05197192RECRUITINGPHASE3
202 participants
INTERVENTIONAL
Bad Saarow, Germany +29 more
Started: Apr 19, 2022
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
NCT06428019RECRUITINGPHASE3
170 participants
INTERVENTIONAL
Tucson, United States +69 more
Started: Aug 5, 2024
A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05057494ACTIVE NOT RECRUITINGPHASE3
607 participants
INTERVENTIONAL
Tucson, United States +36 more
Started: Sep 12, 2022
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
NCT03580928ACTIVE NOT RECRUITINGPHASE2
72 participants
INTERVENTIONAL
Stamford, United States +3 more
Started: Aug 7, 2018
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
NCT03824483RECRUITINGPHASE2
230 participants
INTERVENTIONAL
Evanston, United States +7 more
Started: Feb 22, 2019
Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
NCT06967610RECRUITINGPHASE2
40 participants
INTERVENTIONAL
Houston, United States
Started: Jul 15, 2025
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
NCT03836261ACTIVE NOT RECRUITINGPHASE3
984 participants
INTERVENTIONAL
Los Angeles, United States +169 more
Started: Feb 25, 2019
Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
NCT05336812RECRUITINGPHASE2
52 participants
INTERVENTIONAL
Columbus, United States
Started: Sep 13, 2022
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT04169737RECRUITINGPHASE2
168 participants
INTERVENTIONAL
Houston, United States
Started: Jul 29, 2020
Completed Clinical Trials
7 completed trials for Venetoclax + Obinutuzumab in Chronic lymphoid leukemia
A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia
NCT01685892COMPLETEDPHASE1
82 participants
INTERVENTIONAL
La Jolla, United States +9 more
Started: Nov 29, 2012
Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
NCT02242942COMPLETEDPHASE3
445 participants
INTERVENTIONAL
Gilbert, United States +121 more
Started: Dec 31, 2014
Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL
NCT02758665COMPLETEDPHASE2
41 participants
INTERVENTIONAL
Cologne, Germany +10 more
Started: Sep 1, 2016
Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia
NCT03755947COMPLETEDPHASE2
3 participants
INTERVENTIONAL
Huixquilucan, Mexico
Started: Dec 1, 2018
Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL
NCT03787264COMPLETEDPHASE2
46 participants
INTERVENTIONAL
Cologne, Germany +16 more
Started: Jan 14, 2019
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05105841COMPLETEDPHASE2
20 participants
INTERVENTIONAL
Nagoya, Japan +19 more
Started: Nov 8, 2021
A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy
NCT03406156COMPLETEDPHASE3
120 participants
INTERVENTIONAL
Tempe, United States +14 more
Started: Aug 10, 2018
Showing 20 of 46 total trials